Changping Wu

9.2k citations
140 papers · 7.4k · 3 hit papers · h-index 40

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Inflammatory Biomarkers in Disease Prognosis
  • Hepatology top 1%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Cancer Immunotherapy and Biomarkers 25
    • Colorectal Cancer Treatments and Studies 12
    • Inflammatory Biomarkers in Disease Prognosis 7
    • Lung Cancer Research Studies 5
    • MicroRNA in disease regulation 11
    • Cancer-related molecular mechanisms research 7

Changping Wu

138 papers receiving 7.3k citations

Changping Wu's Hit Papers

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial 2021 · 194 citations
1940+3+6Years since publication250500750

Peers

Changping Wu
Comparison fields: 5 of 111
  • Oncology 2.9k
  • Hepatology 676
  • Cancer Research 721
  • Pulmonary and Respiratory Medicine 1.2k
  • Immunology 680
Replace Davide Melisi with:
Davide Melisi Italy
Carolyn D. Britten United States
Michael J. Pishvaian United States
Zaoqu Liu China
Jasgit C. Sachdev United States
Masayuki Sho Japan
Mohamed Hebbar France
Kwok Wah Chan Hong Kong
John H. Strickler United States
Tetsuo Ohta Japan
Changping Wu relative to Davide Melisi Italy Davide Melisi's profile →
Citations per field
00.5×1.5×2×2.4×
Davide Melisi · 1×
Citations per year

Countries citing papers authored by Changping Wu

Since Specialization
Citations

This map shows the geographic impact of Changping Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changping Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changping Wu more than expected).

Fields of papers citing papers by Changping Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changping Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changping Wu. The network helps show where Changping Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Changping Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Changping Wu Line = papers co-authored together Changping Wu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 140 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Hit paper breakdown →
2016807
2
A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling
Hit paper breakdown →
2019446
3 2006443
4 2018327
5 2014306
6 2016266
7 2015214
8 2017212
9 2014205
10 2016200
11
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Hit paper breakdown →
2021194
12 2014185
13 2022157
14 2018140
15 2013124
16 2014112
17 2017101
18 2014100
19 201997
20 201086

About Changping Wu

Changping Wu is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Hepatology and Immunology, having authored 140 papers that have together received 7.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Gastric Cancer Management and Outcomes (25 papers), Colorectal Cancer Treatments and Studies (12 papers), MicroRNA in disease regulation (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Inflammatory Biomarkers in Disease Prognosis (7 papers), Cancer-related molecular mechanisms research (7 papers) and Lung Cancer Research Studies (5 papers). The work is most often cited by research in Oncology (2.9k citations), Hepatology (676 citations), Cancer Research (721 citations), Pulmonary and Respiratory Medicine (1.2k citations) and Immunology (680 citations). Changping Wu has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Jingting Jiang, Xiao Wei Zheng, Bin Xu, Lujun Chen, Binfeng Lu, Yibei Zhu, Xueguang Zhang, Yiting Geng, Ning Xu and Jiemin Zhao. Their work appears in journals such as Oncotarget, Cellular Physiology and Biochemistry, Medicine, 癌症:英文版 and Journal of Translational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact